Ocular Therapeutix, Inc. (OCUL) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time, please press star zero and a member of our team will be happy to help you. ¶¶ Thank you. © transcript Emily Beynon © transcript Emily Beynon ¶¶ ¶¶ ¶¶ Good morning and welcome to the Ocular Therapeutics first quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. After the prepared remarks, we will conduct a question and answer session. If you would like to ask a question, please press star 1 on your telephone. As a reminder, this conference call is being recorded and will be available for replay on the investor relations section of the Ocular Therapeutics website. I would now like to turn the call over to Ocular's Vice President of Investor Relations, Bill Slattery, Jr. Please go ahead, Mr. Slattery. Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release and filed our quarterly report on Form 10-Q, outlining our financial results and business updates for the first quarter of 2026. During today's call, Ocular's Executive Chairman, President, and CEO, Dr. Praveen Dougal, will summarize recent business highlights before we move to our question and answer session. Joining Dr. Dougal for the Q&A portion of the call will be Donald Notman, Chief Operating Officer, Sanjay Nayak, Chief Strategy Officer, and Steve Myers, Chief Commercial Officer. We refer everyone to this morning's press release and our Form 10-Q for a comprehensive update of our first quarter 2026 financial and business results. During today's call, certain statements we will be making constitute forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995...